Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing ...
Novartis Cosentyx meets primary and all secondary endpoints in phase III trial in patients with polymyalgia rheumatica: Basel Thursday, October 23, 2025, 09:00 Hrs [IST] Novartis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback